{"id":"https://openalex.org/W2490888802","doi":"https://doi.org/10.1212/wnl.86.16_supplement.s28.006","title":"Effect of Deflazacort and Prednisone versus Placebo on Muscle Strength in Boys with Duchenne Muscular Dystrophy Who Have Lost Ambulation: Results from the Deflazacort Clinical Trial Program (S28.006)","display_name":"Effect of Deflazacort and Prednisone versus Placebo on Muscle Strength in Boys with Duchenne Muscular Dystrophy Who Have Lost Ambulation: Results from the Deflazacort Clinical Trial Program (S28.006)","publication_year":2016,"publication_date":"2016-04-05","ids":{"openalex":"https://openalex.org/W2490888802","doi":"https://doi.org/10.1212/wnl.86.16_supplement.s28.006","mag":"2490888802"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.86.16_supplement.s28.006","doi":"https://doi.org/10.1212/wnl.86.16_supplement.s28.006","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.86.16_supplement.s28.006","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015590542","display_name":"Timothy M. Cunniff","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Timothy Cunniff","raw_affiliation_strings":["Marathon Pharmaceuticals, LLC Chicago IL United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marathon Pharmaceuticals, LLC Chicago IL United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082707084","display_name":"Stephen P. Wanaski","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephen Wanaski","raw_affiliation_strings":["Marathon Pharmaceuticals, LLC Chicago IL United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marathon Pharmaceuticals, LLC Chicago IL United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007434885","display_name":"Jordan S. Dubow","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jordan Dubow","raw_affiliation_strings":["Marathon Pharmaceuticals, LLC Northbrook IL United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marathon Pharmaceuticals, LLC Northbrook IL United States","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5073361852","display_name":"James Meyer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"James Meyer","raw_affiliation_strings":["Marathon Pharmaceuticals, LLC Northbrook IL United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marathon Pharmaceuticals, LLC Northbrook IL United States","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.06083903,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"86","issue":"16_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10441","display_name":"Muscle Physiology and Disorders","score":0.9653000235557556,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10441","display_name":"Muscle Physiology and Disorders","score":0.9653000235557556,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12400","display_name":"Neurogenetic and Muscular Disorders Research","score":0.02239999920129776,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12421","display_name":"Adrenal Hormones and Disorders","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/deflazacort","display_name":"deflazacort","score":0.9990000128746033},{"id":"https://openalex.org/keywords/prednisone","display_name":"prednisone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/muscle-strength","display_name":"muscle strength","score":0.8190000057220459},{"id":"https://openalex.org/keywords/non-ambulatory-patients","display_name":"non-ambulatory patients","score":0.7670000195503235},{"id":"https://openalex.org/keywords/glucocorticoid-therapy","display_name":"glucocorticoid therapy","score":0.8970000147819519},{"id":"https://openalex.org/keywords/mrc-scale","display_name":"MRC scale","score":0.5070000290870667},{"id":"https://openalex.org/keywords/boys","display_name":"boys","score":0.4269999861717224},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.6420000195503235},{"id":"https://openalex.org/keywords/loss-of-ambulation","display_name":"loss of ambulation","score":0.5680000185966492},{"id":"https://openalex.org/keywords/post-hoc-subgroup-analysis","display_name":"post hoc subgroup analysis","score":0.8109999895095825}],"concepts":[{"id":"https://openalex.org/C2776376305","wikidata":"https://www.wikidata.org/wiki/Q779118","display_name":"Deflazacort","level":3,"score":0.9978621006011963},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8404322862625122},{"id":"https://openalex.org/C2778943923","wikidata":"https://www.wikidata.org/wiki/Q1648484","display_name":"Duchenne muscular dystrophy","level":2,"score":0.8005313873291016},{"id":"https://openalex.org/C2778720950","wikidata":"https://www.wikidata.org/wiki/Q424972","display_name":"Prednisone","level":2,"score":0.6834145188331604},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6796934008598328},{"id":"https://openalex.org/C2779030066","wikidata":"https://www.wikidata.org/wiki/Q1137767","display_name":"Muscular dystrophy","level":2,"score":0.6172654628753662},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.5157785415649414},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.30189019441604614},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1822010576725006},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.05900675058364868},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.86.16_supplement.s28.006","doi":"https://doi.org/10.1212/wnl.86.16_supplement.s28.006","is_oa":false,"landing_page_url":"https://doi.org/10.1212/wnl.86.16_supplement.s28.006","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2508926647","https://openalex.org/W2508308791","https://openalex.org/W2518245700","https://openalex.org/W2143033848","https://openalex.org/W2508371728","https://openalex.org/W2562578514","https://openalex.org/W2979393210","https://openalex.org/W2096328571","https://openalex.org/W2549521318","https://openalex.org/W2774089318"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"assess":[2],"the":[3,26,35,61,101,146,207,233,241,274],"effects":[4,242],"of":[5,30,37,63,81,104,119,140,161,189,195,216,243,277],"deflazacort":[6,65,89,105,162,198,219,226,244,260,278],"and":[7,69,77,90,163,223,245],"prednisone":[8,74,91,107,164,208,215,246],"on":[9,247],"muscle":[10,120,169,204,248,265],"strength":[11,121,170,205,249,266],"in":[12,39,130,168,203,250,263,267,291],"boys":[13,46,82,252,268],"with":[14,83,253],"DMD":[15],"who":[16,132,269],"have":[17,47],"lost":[18,48,271],"ambulation":[19],"Background:":[20],"Duchenne":[21],"Muscular":[22],"Dystrophy":[23],"(DMD)":[24],"is":[25,232,279],"most":[27],"common":[28],"type":[29],"muscular":[31],"dystrophy.":[32],"Glucocorticoids":[33],"are":[34],"mainstay":[36],"treatment":[38,80,148],"ambulatory":[40,293],"patients,":[41],"but":[42],"often":[43],"discontinued":[44],"after":[45],"ambulation.":[49,272],"Design/Methods:":[50],"This":[51,231],"randomized,":[52,236],"double-blind,":[53],"placebo-controlled,":[54],"active":[55],"comparator,":[56],"Phase":[57],"3":[58],"study":[59,238],"evaluated":[60],"efficacy":[62],"two":[64,102],"doses":[66,103,160,283],"(0.9":[67],"mg/kg/day":[68,178,221,228],"1.2":[70,177,227],"mg/kg/day)":[71,76],"compared":[72,88,100],"to":[73,92,106,110,145,239,287],"(0.75":[75],"placebo":[78,93,172,182],"for":[79,218,225],"DMD.":[84,254],"The":[85,97],"first":[86,234],"segment":[87,99],"over":[94,181],"12":[95,109,157,184],"weeks.":[96,112],"second":[98],"from":[108],"52":[111,193],"We":[113],"conducted":[114],"a":[115,123],"post-hoc":[116],"subgroup":[117],"analysis":[118],"(using":[122],"modified":[124],"11-point":[125],"medical":[126],"research":[127],"council":[128],"scale)":[129],"patients":[131,151,173],"were":[133,143,152],"non-ambulatory":[134,153,251],"at":[135,154,176,183],"baseline.":[136,155],"Results:":[137],"A":[138],"total":[139],"196":[141],"participants":[142],"randomized":[144],"4":[147],"groups;":[149],"45":[150],"At":[156],"weeks,":[158],"both":[159,197],"had":[165,270],"numerical":[166,201],"improvement":[167,202],"while":[171,206],"worsened.":[174],"Deflazacort":[175],"reached":[179],"significance":[180],"weeks":[185,194],"(LS":[186],"mean":[187,212],"change":[188,213],"0.49;":[190],"p<0.05).":[191],"Over":[192],"treatment,":[196],"groups":[199],"showed":[200],"group":[209],"worsened":[210],"[LS":[211],"vs.":[214],"0.27":[217],"0.9":[220,280],"(p=0.387)":[222],"0.45":[224],"(p=0.088)].":[229],"Conclusions:":[230],"prospective,":[235],"blinded":[237],"demonstrate":[240],"In":[255],"this":[256],"small,":[257],"sub-set":[258],"analysis,":[259],"demonstrated":[261],"trends":[262],"improving":[264],"Although":[273],"recommended":[275],"dose":[276],"mg/kg/day,":[281],"increased":[282],"may":[284],"be":[285],"required":[286],"preserve":[288],"motor":[289],"function":[290],"post-":[292],"boys;":[294],"these":[295],"data":[296],"merit":[297],"further":[298],"investigation.":[299]},"counts_by_year":[{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-08-23T00:00:00"}